title: Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
authors: G
authors: G
authors: Georgiou
authors: A
authors: A
authors: Efthymiou
authors: I
authors: I
authors: Vardounioti
authors: G
authors: G
authors: Boutsikas
authors: M K
authors: MK
authors: Angelopoulou
authors: T P
authors: TP
authors: Vassilakopoulos
authors: M-C
authors: MC
authors: Kyrtsonis
authors: E
authors: E
authors: Plata
authors: P
authors: P
authors: Tofas
authors: A
authors: A
authors: Bitsani
authors: V
authors: V
authors: Bartzi
authors: I
authors: I
authors: Pessach
authors: M
authors: M
authors: Dimou
authors: P
authors: P
authors: Panayiotidis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D010879:Piperazines; D011743:Pyrimidines; D000090243:Nucleophosmin; D000068877:Imatinib Mesylate